Long-Term Tolerance and Skin Allograft Survival in CD200tg Mice After Autologous Marrow Transplantation

2014 ◽  
Vol 98 (12) ◽  
pp. 1271-1278 ◽  
Author(s):  
Reginald Gorczynski ◽  
Zhiqi Chen ◽  
Ismat Khatri ◽  
Kai Yu
2019 ◽  
Vol 116 (27) ◽  
pp. 13508-13516 ◽  
Author(s):  
Nina Pilat ◽  
Mario Wiletel ◽  
Anna M. Weijler ◽  
Romy Steiner ◽  
Benedikt Mahr ◽  
...  

Injection of Interleukin-2 (IL-2) complexed with a particular anti–IL-2 monoclonal antibody (mab) JES6-1 has been shown to selectively expand CD4+Foxp3+ T regulatory T cells (Tregs) in vivo. Although the potency of this approach with regard to transplantation has already been proven in an islet transplantation model, skin graft survival could not be prolonged. Since the latter is relevant to human allograft survival, we sought to improve the efficiency of IL-2 complex (cplx) treatment for skin allograft survival in a stringent murine skin graft model. Here, we show that combining low doses of IL-2 cplxs with rapamycin and blockade of the inflammatory cytokine IL-6 leads to long-term (>75 d) survival of major histocompatibility complex-different skin allografts without the need for immunosuppression. Allograft survival was critically dependent on CD25+FoxP3+ Tregs and was not accompanied by impaired responsiveness toward donor alloantigens in vitro after IL-2 cplx treatment was stopped. Furthermore, second donor-type skin grafts were rejected and provoked rejection of the primary graft, suggesting that operational tolerance is not systemic but restricted to the graft. These findings plus the lack of donor-specific antibody formation imply that prolonged graft survival was largely a reflection of immunological ignorance. The results may represent a potentially clinically translatable strategy for the development of protocols for tolerance induction.


The Lancet ◽  
1986 ◽  
Vol 327 (8471) ◽  
pp. 14-15 ◽  
Author(s):  
BruceM. Achauer ◽  
KirbyS. Black ◽  
KennethS. Waxman ◽  
CharlesW. Hewitt ◽  
SuzanneE. Martinez ◽  
...  

Blood ◽  
1998 ◽  
Vol 91 (1) ◽  
pp. 324-330 ◽  
Author(s):  
Liming Yang ◽  
Barb Du Temple ◽  
Qasim Khan ◽  
Li Zhang

Abstract Pretransplantation donor-specific transfusion (DST) can enhance allograft survival in man and animals. However, due to the lack of a specific marker to identify donor-reactive cells in vivo in man and normal (nontransgenic) animals, the underlying mechanism remains unknown. In this study, we use 2CF1 transgenic mice expressing a transgenic T-cell receptor (TCR) specifically recognizing Ld, a major histocompatibility complex (MHC) class I molecule, to delineate the role of DST in long-term skin allograft survival and its underlying mechanisms. Our main findings include: (1) in the absence of any other immunosuppressive treatment, a single dose pretransplantation infusion of viable splenocytes from an Ld+ donor is sufficient to induce permanent donor-specific skin allograft survival in 2CF1anti-Ld TCR transgenic mice; (2) DST leads to a deletion of the majority (>60%) of donor-reactive T cells in the periphery of the recipient. However, deletion does not necessarily result in tolerance; (3) remaining donor-reactive T cells from DST-treated mice are fully responsive to Ld in vitro, and can suppress the antidonor response of naive T cells in vitro only when exogenous interleukin (IL)-4 is provided; and (4) the sera level of IL-4 in DST-treated tolerant mice is significantly increased. These results suggest that the generation of a subset of T cells with the potential to specifically inhibit antidonor responses, together with promotion of IL-4 production in recipients, may be important mechanisms for the induction and maintenance of antigen-specific tolerance.


2005 ◽  
Vol 37 (5) ◽  
pp. 2309-2314 ◽  
Author(s):  
M. Siemionow ◽  
K. Ozer ◽  
D. Izycki ◽  
M. Unsal ◽  
A. Klimczak

2018 ◽  
Vol 102 (4) ◽  
pp. e128-e136 ◽  
Author(s):  
Kiyohiko Hotta ◽  
Tetsu Oura ◽  
Abbas Dehnadi ◽  
Svjetlan Boskovic ◽  
Masatoshi Matsunami ◽  
...  

Blood ◽  
1998 ◽  
Vol 91 (1) ◽  
pp. 324-330
Author(s):  
Liming Yang ◽  
Barb Du Temple ◽  
Qasim Khan ◽  
Li Zhang

Pretransplantation donor-specific transfusion (DST) can enhance allograft survival in man and animals. However, due to the lack of a specific marker to identify donor-reactive cells in vivo in man and normal (nontransgenic) animals, the underlying mechanism remains unknown. In this study, we use 2CF1 transgenic mice expressing a transgenic T-cell receptor (TCR) specifically recognizing Ld, a major histocompatibility complex (MHC) class I molecule, to delineate the role of DST in long-term skin allograft survival and its underlying mechanisms. Our main findings include: (1) in the absence of any other immunosuppressive treatment, a single dose pretransplantation infusion of viable splenocytes from an Ld+ donor is sufficient to induce permanent donor-specific skin allograft survival in 2CF1anti-Ld TCR transgenic mice; (2) DST leads to a deletion of the majority (>60%) of donor-reactive T cells in the periphery of the recipient. However, deletion does not necessarily result in tolerance; (3) remaining donor-reactive T cells from DST-treated mice are fully responsive to Ld in vitro, and can suppress the antidonor response of naive T cells in vitro only when exogenous interleukin (IL)-4 is provided; and (4) the sera level of IL-4 in DST-treated tolerant mice is significantly increased. These results suggest that the generation of a subset of T cells with the potential to specifically inhibit antidonor responses, together with promotion of IL-4 production in recipients, may be important mechanisms for the induction and maintenance of antigen-specific tolerance.


Sign in / Sign up

Export Citation Format

Share Document